Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1

Show other versions (1)

Bibliographic Details
Main Authors:	Ahmed T, Borthwick N, Yang H, Hancock G, Yorke L, Ebrahimsa U, Rose A, Black A, Hayton E, McMichael A, Dorrell L, Hanke T
Format:	Article
Language:	English
Published:	BMC 2012-09-01
Series:	Retrovirology

Similar Items

Recombinant DNA/MVA/ChAdV-63-elicited T cells specific for conserved regions of the HIV-1 proteome recognize HIV-1 infected cells and suppress HIV-1
by: Ahmed, T, et al.
Published: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick, N, et al.
Published: (2012)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial
by: Borthwick NJ, et al.
Published: (2012-09-01)

Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and ChAdV-63 in a phase I/IIa clinical trial
by: Hanke, T, et al.
Published: (2012)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1
by: Borthwick, N, et al.
Published: (2014)

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.
by: Borthwick, N, et al.
Published: (2014)

IL-10 Receptor Blockade Enhances CD4 and CD8 T Cell Responses to a Simian Adenovirus-Vectored HIV-1 Vaccine, ChAdV63.HIVconsv
by: Clutton, G, et al.
Published: (2013)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens
by: Moyo, N, et al.
Published: (2017)

Characterisation of T cells induced by candidate prophylactic vaccines encoding a HIV-1 conserved immunogen in phase I/IIa trial HIVCORE002
by: Ahmed, T, et al.
Published: (2011)

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens.
by: Nathifa Moyo, et al.
Published: (2017-01-01)

Targeting HIV-1 Where It Hurts
by: Ahmed, T, et al.
Published: (2013)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
by: Dorrell, L, et al.
Published: (2007)

MVA as a vector for vaccines against HIV-1.
by: Im, E, et al.
Published: (2004)

Targeting HIV-1 where it hurts
by: Borthwick, N, et al.
Published: (2013)

Detection of broad functional gag-specific CD4+T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
by: Ondondo, B, et al.
Published: (2006)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
by: Howles, S, et al.
Published: (2010)

pTHr.HIVA and MVA.HIVA vaccines (gag p24/p17) augment CD4+T cell responses in chronically infected HIV-1 patients on HAART
by: Ondondo, B, et al.
Published: (2005)

Phase I Clinical Trial HIV-CORE002 of a Universal T-cell Vaccine: One Year Follow On and Epitope Mapping
by: Borthwick, N, et al.
Published: (2013)

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
by: Joachim A, et al.
Published: (2012-09-01)

Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
by: Rowland-Jones Sarah L, et al.
Published: (2006-12-01)

Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
by: Hancock, G, et al.
Published: (2017)

HIV-1: from escapism to conservatism.
by: Hanke, T, et al.
Published: (2011)

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques
by: Rosario, M, et al.
Published: (2012)

Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques.
by: Rosario, M, et al.
Published: (2012)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice.
by: Ondondo, B, et al.
Published: (2013)

Absence of systemic toxicity changes following intramuscular administration of novel pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv vaccines to BALB/c mice
by: Ondondo, B, et al.
Published: (2013)

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
by: Mwau, M, et al.
Published: (2004)

Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection.
by: Yang, H, et al.
Published: (2013)

Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection
by: Yang, H, et al.
Published: (2013)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
by: Ashley C. Beavis, et al.
Published: (2023-07-01)

Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.
by: Núria Climent, et al.
Published: (2011-01-01)

The HIVconsv Vaccines Induce Polyfunctional and Highly Proliferative T Cells that Control In Vitro HIV Replication: HIV-CORE002 Phase-I Clinical Trial
by: Ondondo, B, et al.
Published: (2013)

Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
by: Im, E, et al.
Published: (2006)

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.
by: Agricola Joachim, et al.
Published: (2015-01-01)

Novel Nested Peptide Epitopes Recognized by CD4<sup>+</sup> T Cells Induced by HIV-1 Conserved-Region Vaccines
by: Nicola Borthwick, et al.
Published: (2020-01-01)

Therapeutic vaccination following early antiretroviral therapy elicits highly functional T cell responses against conserved HIV-1 regions
by: Jakub Kopycinski, et al.
Published: (2023-10-01)

PedVacc001:Safety and Immunogenicity of a Candidate HIV-1 Vaccine, MVA.HIVA, Administered to Healthy Gambian Infants Born to HIV-1/2-Uninfected Mothers
by: Afolabi, M, et al.
Published: (2011)

Cytotoxic T-cell antagonism in HIV-1
by: Klenerman, P, et al.
Published: (1996)

HIV-1-neutralizing antibody 1 induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
by: Capucci, S, et al.
Published: (2017)

Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.
by: Ondondo, B, et al.
Published: (2006)